{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T18:23:14Z","timestamp":1790619794987,"version":"4.1.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,6,18]],"date-time":"2019-06-18T00:00:00Z","timestamp":1560816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,6,18]],"date-time":"2019-06-18T00:00:00Z","timestamp":1560816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1038\/s41416-019-0502-x","type":"journal-article","created":{"date-parts":[[2019,6,17]],"date-time":"2019-06-17T23:04:55Z","timestamp":1560812695000},"page":"150-156","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["The combination of complex karyotype subtypes and IGHV mutational status identifies new prognostic and predictive groups in chronic lymphocytic leukaemia"],"prefix":"10.1038","volume":"121","author":[{"given":"Andrea","family":"Visentin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Bonaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gian Matteo","family":"Rigolin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca Romana","family":"Mauro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Martines","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Frezzato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Imbergamo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo","family":"Scomazzon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Pravato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Antonella","family":"Bardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Cavallari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Volta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Cavazzini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Nanni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Del Giudice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Facco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Guarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianpietro","family":"Semenzato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Fo\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Cuneo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Livio","family":"Trentin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,6,18]]},"reference":[{"key":"502_CR1","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.critrevonc.2016.06.003","volume":"104","author":"L Scarfo","year":"2016","unstructured":"Scarfo, L., Ferreri, A. J. & Ghia, P. Chronic lymphocytic leukaemia. Crit. Rev. Oncol. hematol. 104, 169\u2013182 (2016).","journal-title":"Crit. Rev. Oncol. hematol.."},{"key":"502_CR2","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/j.clml.2015.06.001","volume":"15","author":"A Visentin","year":"2015","unstructured":"Visentin, A., Facco, M., Frezzato, F., Castelli, M., Trimarco, V., Martini, V. et al. Integrated CLL scoring system, a new and simple index to predict time to treatment and overall survival in patients with chronic lymphocytic leukemia. Clin. Lymphoma Myeloma Leuk. 15, 612\u201320 e1-5 (2015).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"502_CR3","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","volume":"131","author":"M Hallek","year":"2018","unstructured":"Hallek, M., Cheson, B. D., Catovsky, D., Caligaris-Cappio, F., Dighiero, G., Dohner, H. et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood 131, 2745\u20132760 (2018).","journal-title":"Blood"},{"key":"502_CR4","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1002\/ajh.23618","volume":"89","author":"P Baliakas","year":"2014","unstructured":"Baliakas, P., Iskas, M., Gardiner, A., Davis, Z., Plevova, K., Nguyen-Khac, F. et al. Chromosomal translocations and karyotype complexity in chronic lymphocytic leukemia: a systematic reappraisal of classic cytogenetic data. Am. J. Hematol. 89, 249\u2013255 (2014).","journal-title":"Am. J. Hematol."},{"key":"502_CR5","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1182\/blood-2016-01-691550","volume":"128","author":"CD Herling","year":"2016","unstructured":"Herling, C. D., Klaumunzer, M., Rocha, C. K., Altmuller, J., Thiele, H., Bahlo, J. et al. Complex karyotypes and KRAS and POT1 mutations impact outcome in CLL after chlorambucil-based chemotherapy or chemoimmunotherapy. Blood 128, 395\u2013404 (2016).","journal-title":"Blood"},{"key":"502_CR6","doi-asserted-by":"publisher","first-page":"3495","DOI":"10.1182\/blood-2017-03-772285","volume":"129","author":"GM Rigolin","year":"2017","unstructured":"Rigolin, G. M., Cavallari, M., Quaglia, F. M., Formigaro, L., Lista, E., Urso, A. et al. In CLL, comorbidities and the complex karyotype are associated with an inferior outcome independently of CLL-IPI. Blood 129, 3495\u20133498 (2017).","journal-title":"Blood"},{"key":"502_CR7","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1002\/hon.2349","volume":"35","author":"Y Le Bris","year":"2017","unstructured":"Le Bris, Y., Struski, S., Guieze, R., Rouvellat, C., Prade, N., Troussard, X. et al. Major prognostic value of complex karyotype in addition to TP53 and IGHV mutational status in first-line chronic lymphocytic leukemia. Hematol. Oncol. 35, 664\u2013670 (2017).","journal-title":"Hematol. Oncol."},{"key":"502_CR8","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1002\/gcc.22293","volume":"54","author":"GM Rigolin","year":"2015","unstructured":"Rigolin, G. M., del Giudice, I., Formigaro, L., Saccenti, E., Martinelli, S., Cavallari, M. et al. Chromosome aberrations detected by conventional karyotyping using novel mitogens in chronic lymphocytic leukemia: Clinical and biologic correlations. Genes Chromosomes Cancer 54, 818\u2013826 (2015).","journal-title":"Genes Chromosomes Cancer"},{"key":"502_CR9","doi-asserted-by":"publisher","first-page":"3016","DOI":"10.1182\/blood-2010-08-304683","volume":"117","author":"XC Badoux","year":"2011","unstructured":"Badoux, X. C., Keating, M. J., Wang, X., O\u2019Brien, S. M., Ferrajoli, A., Faderl, S. et al. Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL. Blood 117, 3016\u20133024 (2011).","journal-title":"Blood"},{"key":"502_CR10","doi-asserted-by":"crossref","first-page":"3362","DOI":"10.1182\/blood-2017-01-763003","volume":"129","author":"MA Anderson","year":"2017","unstructured":"Anderson, M. A., Tam, C., Lew, T. E., Juneja, S., Juneja, M., Westerman, D. et al. Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax. Blood 129, 3362\u20133370 (2017).","journal-title":"Blood"},{"key":"502_CR11","doi-asserted-by":"publisher","first-page":"3612","DOI":"10.1002\/cncr.29566","volume":"121","author":"PA Thompson","year":"2015","unstructured":"Thompson, P. A., O\u2019Brien, S. M., Wierda, W. G., Ferrajoli, A., Stingo, F., Smith, S. C. et al. Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens. Cancer 121, 3612\u20133621 (2015).","journal-title":"Cancer"},{"key":"502_CR12","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1111\/bjh.15174","volume":"181","author":"GM Rigolin","year":"2018","unstructured":"Rigolin, G. M., Saccenti, E., Guardalben, E., Cavallari, M., Formigaro, L., Zagatti, B. et al. In chronic lymphocytic leukaemia with complex karyotype, major structural abnormalities identify a subset of patients with inferior outcome and distinct biological characteristics. Br. J. Haematol. 181, 229\u2013233 (2018).","journal-title":"Br. J. Haematol."},{"key":"502_CR13","doi-asserted-by":"publisher","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","volume":"111","author":"M Hallek","year":"2008","unstructured":"Hallek, M., Cheson, B. D., Catovsky, D., Caligaris-Cappio, F., Dighiero, G., Dohner, H. et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 111, 5446\u20135456 (2008).","journal-title":"Blood"},{"key":"502_CR14","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1002\/ajh.23979","volume":"90","author":"M Hallek","year":"2015","unstructured":"Hallek, M. Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment. Am. J. Hematol. 90, 446\u2013460 (2015).","journal-title":"Am. J. Hematol."},{"key":"502_CR15","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1038\/leu.2011.49","volume":"25","author":"AW Langerak","year":"2011","unstructured":"Langerak, A. W., Davi, F., Ghia, P., Hadzidimitriou, A., Murray, F., Potter, K. N. et al. Immunoglobulin sequence analysis and prognostication in CLL: guidelines from the ERIC review board for reliable interpretation of problematic cases. Leukemia 25, 979\u2013984 (2011).","journal-title":"Leukemia"},{"key":"502_CR16","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1038\/s41375-017-0007-7","volume":"32","author":"J Malcikova","year":"2018","unstructured":"Malcikova, J., Tausch, E., Rossi, D., Sutton, L. A., Soussi, T., Zenz, T. et al. ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-update on methodological approaches and results interpretation. Leukemia 32, 1070\u20131080 (2018).","journal-title":"Leukemia"},{"key":"502_CR17","doi-asserted-by":"crossref","first-page":"80916","DOI":"10.18632\/oncotarget.13106","volume":"7","author":"G Blanco","year":"2016","unstructured":"Blanco, G., Puiggros, A., Baliakas, P., Athanasiadou, A., Garcia-Malo, M., Collado, R. et al. Karyotypic complexity rather than chromosome 8 abnormalities aggravates the outcome of chronic lymphocytic leukemia patients with TP53 aberrations. Oncotarget 7, 80916\u201380924 (2016).","journal-title":"Oncotarget"},{"key":"502_CR18","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1080\/10428194.2017.1376748","volume":"59","author":"N Kreinitz","year":"2018","unstructured":"Kreinitz, N., Polliack, A. & Tadmor, T. Chronic lymphocytic leukemia is becoming more complex: how to define complex karyotype? Leuk. Lymphoma 59, 521\u2013522 (2018).","journal-title":"Leuk. Lymphoma"},{"key":"502_CR19","doi-asserted-by":"publisher","unstructured":"Visentin A., Facco A., Gurrieri C., Pagnin E., Martini V., Imbergamo S., et al. Prognostic and predictive impact of IGHV mutational status and load in chronic lymphocytic leukemia: focus on FCR and BR treatments. Clin. Lymphoma Myeloma Leuk. \n                    https:\/\/doi.org\/10.1016\/j.clml.2019.03.002\n                    \n                   (2019).","DOI":"10.1016\/j.clml.2019.03.002"},{"key":"502_CR20","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1093\/annonc\/mdy021","volume":"29","author":"S Raponi","year":"2018","unstructured":"Raponi, S., Del Giudice, I., Marinelli, M., Wang, J., Cafforio, L., Ilari, C. et al. Genetic landscape of ultra-stable chronic lymphocytic leukemia patients. Ann. Oncol. 29, 966\u2013972 (2018).","journal-title":"Ann. Oncol."},{"issue":"Web Server issu","key":"502_CR21","doi-asserted-by":"publisher","first-page":"W503","DOI":"10.1093\/nar\/gkn316","volume":"36","author":"X Brochet","year":"2008","unstructured":"Brochet, X., Lefranc, M. P. & Giudicelli, V. IMGT\/V-QUEST: the highly customized and integrated system for IG and TR standardized V-J and V-D-J sequence analysis. Nucleic Acids Res. 36(Web Server issue), W503\u2013W508 (2008).","journal-title":"Nucleic Acids Res."},{"key":"502_CR22","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1182\/blood.V94.6.1848","volume":"94","author":"TJ Hamblin","year":"1999","unstructured":"Hamblin, T. J., Davis, Z., Gardiner, A., Oscier, D. G. & Stevenson, F. K. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 94, 1848\u20131854 (1999).","journal-title":"Blood"},{"key":"502_CR23","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","volume":"343","author":"H Dohner","year":"2000","unstructured":"Dohner, H., Stilgenbauer, S., Benner, A., Leupolt, E., Krober, A., Bullinger, L. et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N. Engl. J. Med. 343, 1910\u20131916 (2000).","journal-title":"N. Engl. J. Med."},{"key":"502_CR24","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","volume":"376","author":"M Hallek","year":"2010","unstructured":"Hallek, M., Fischer, K., Fingerle-Rowson, G., Fink, A. M., Busch, R., Mayer, J. et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 376, 1164\u20131174 (2010).","journal-title":"Lancet"},{"key":"502_CR25","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/S1470-2045(16)30051-1","volume":"17","author":"B Eichhorst","year":"2016","unstructured":"Eichhorst, B., Fink, A. M., Bahlo, J., Busch, R., Kovacs, G., Maurer, C. et al. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol. 17, 928\u2013942 (2016).","journal-title":"Lancet Oncol."},{"key":"502_CR26","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1002\/ajh.24660","volume":"92","author":"J Delgado","year":"2017","unstructured":"Delgado, J., Doubek, M., Baumann, T., Kotaskova, J., Molica, S., Mozas, P. et al. Chronic lymphocytic leukemia: a prognostic model comprising only two biomarkers (IGHV mutational status and FISH cytogenetics) separates patients with different outcome and simplifies the CLL-IPI. Am. J. Hematol. 92, 375\u2013380 (2017).","journal-title":"Am. J. Hematol."},{"key":"502_CR27","doi-asserted-by":"publisher","first-page":"e299","DOI":"10.3324\/haematol.2015.140202","volume":"101","author":"P Baliakas","year":"2016","unstructured":"Baliakas, P., Puiggros, A., Xochelli, A., Sutton, L. A., Nguyen-Khac, F., Gardiner, A. et al. Additional trisomies amongst patients with chronic lymphocytic leukemia carrying trisomy 12: the accompanying chromosome makes a difference. Haematologica 101, e299\u2013e302 (2016).","journal-title":"Haematologica"},{"key":"502_CR28","doi-asserted-by":"publisher","first-page":"54297","DOI":"10.18632\/oncotarget.17350","volume":"8","author":"A Puiggros","year":"2017","unstructured":"Puiggros, A., Collado, R., Calasanz, M. J., Ortega, M., Ruiz-Xiville, N., Rivas-Delgado, A. et al. Patients with chronic lymphocytic leukemia and complex karyotype show an adverse outcome even in absence of TP53\/ATM FISH deletions. Oncotarget 8, 54297\u201354303 (2017).","journal-title":"Oncotarget"},{"issue":"11","key":"502_CR29","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1182\/blood-2018-09-873083","volume":"133","author":"Panagiotis Baliakas","year":"2019","unstructured":"Baliakas P., Jeromin S., Iskas M., Puiggros A., Plevova K., Nguyen-Khac F. et al. Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations and clinical impact. Blood 133, 1205\u20131216 (2019). \n                    https:\/\/doi.org\/10.1182\/blood-2018-09-873083","journal-title":"Blood"},{"key":"502_CR30","doi-asserted-by":"publisher","first-page":"56976","DOI":"10.18632\/oncotarget.10927","volume":"7","author":"R Guieze","year":"2016","unstructured":"Guieze, R., Pages, M., Veronese, L., Combes, P., Lemal, R., Gay-Bellile, M. et al. Telomere status in chronic lymphocytic leukemia with TP53 disruption. Oncotarget 7, 56976\u201356985 (2016).","journal-title":"Oncotarget"},{"key":"502_CR31","doi-asserted-by":"publisher","first-page":"e253","DOI":"10.3324\/haematol.2016.157669","volume":"102","author":"E Rampazzo","year":"2017","unstructured":"Rampazzo, E., Bojnik, E., Trentin, L., Bonaldi, L., Del Bianco, P., Frezzato, F. et al. Role of miR-15a\/miR-16-1 and the TP53 axis in regulating telomerase expression in chronic lymphocytic leukemia. Haematologica 102, e253\u2013e256 (2017).","journal-title":"Haematologica"},{"key":"502_CR32","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1007\/s00277-017-3055-1","volume":"96","author":"K Thomay","year":"2017","unstructured":"Thomay, K., Fedder, C., Hofmann, W., Kreipe, H., Stadler, M., Titgemeyer, J. et al. Telomere shortening, TP53 mutations and deletions in chronic lymphocytic leukemia result in increased chromosomal instability and breakpoint clustering in heterochromatic regions. Ann. Hematol. 96, 1493\u20131500 (2017).","journal-title":"Ann. Hematol."},{"key":"502_CR33","doi-asserted-by":"publisher","unstructured":"Jebaraj B. M. C., Tausch E., Landau D. A., Bahlo J., Robrecht S., Taylor-Weiner A. N., et al. Short telomeres are associated with inferior outcome, genomic complexity, and clonal evolution in chronic lymphocytic leukemia. Leukemia 2019. \n                    https:\/\/doi.org\/10.1038\/s41375-019-0446-4\n                    \n                  .","DOI":"10.1038\/s41375-019-0446-4"},{"key":"502_CR34","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1182\/blood-2015-05-647925","volume":"126","author":"D Rossi","year":"2015","unstructured":"Rossi, D., Terzi-di-Bergamo, L., De Paoli, L., Cerri, M., Ghilardi, G., Chiarenza, A. et al. Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia. Blood 126, 1921\u20131924 (2015).","journal-title":"Blood"},{"key":"502_CR35","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1182\/blood-2015-06-651125","volume":"127","author":"K Fischer","year":"2016","unstructured":"Fischer, K., Bahlo, J., Fink, A. M., Goede, V., Herling, C. D., Cramer, P. et al. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood 127, 208\u2013215 (2016).","journal-title":"Blood"},{"key":"502_CR36","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1182\/blood-2015-09-667675","volume":"127","author":"PA Thompson","year":"2016","unstructured":"Thompson, P. A., Tam, C. S., O\u2019Brien, S. M., Wierda, W. G., Stingo, F., Plunkett, W. et al. Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. Blood 127, 303\u2013309 (2016).","journal-title":"Blood"},{"key":"502_CR37","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1038\/s41375-018-0100-6","volume":"32","author":"M Gentile","year":"2018","unstructured":"Gentile, M., Shanafelt, T. D., Reda, G., Mauro, F. R., Zirlik, K., Ciolli, S. et al. Validation of a biological score to predict response in chronic lymphocytic leukemia patients treated front-line with bendamustine and rituximab. Leukemia 32, 1869\u20131873 (2018).","journal-title":"Leukemia"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41416-019-0502-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41416-019-0502-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41416-019-0502-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:05:14Z","timestamp":1684616714000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-019-0502-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,18]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["502"],"URL":"https:\/\/doi.org\/10.1038\/s41416-019-0502-x","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,18]]},"assertion":[{"value":"27 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.V. received honoraria from Janssen and Abbvie. L.T. received research funding by Gilead and Janssen, advisory board for Roche, Shire and Abbvie. G.M.R. received research funding by Gilead. F.R.M. advisory board for Janssen, Shire and Abbvie. A.C. advisory board and speaker bureau for Roche, Abbvie, Gilead and Janssen. G.S. board member of Abbvie, Roche, Janssen and Celgene. R.F. advisory board or speaker bureau for Roche, Abbvie, Celgene, Incyte, Amgen, Janssen, Celtrion, Gilead and Novartis. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the local research ethics committee of Padua hospital and informed consent was obtained from all patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"This work was supported by funds from Associazione Italiana per la Ricerca sul Cancro (A.I.R.C.) projects to L.T. (IG-15397), Gilead fellowship program 2017 and 2018 to L.T., Special Program \u2018Metastatic disease: the key unmet need in oncology\u2019, AIRC 5\u2009\u00d7\u20091000 (No. 21198) to R.F., Fondo di Ateneo per la Ricerca 2016, 2017 of the University of Ferrara to GMR and F.C., Fondo di Incentivazione alla Ricerca 2017 of the University of Ferrara to G.M.R., Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca PRIN 2015 to A.C. (2015ZMRFEA). A.V. received a research fellowship from the University of Padua supported by ONLUS Ricerca per Credere nella Vita (RCV), Padua, Italy.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"All patients gave consent to the publication of anonymous data.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The datasets generated and analysed during the current study are not publicly available due to the data protection and lack of consent from the patients. Access to data is strictly limited to the researchers who have obtained permission for data processing.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Note"}}]}}